Study explores long-term effects of Japan’s COVID-19 health advisories

Boehringer In­gel­heim is part­ner­ing with Chi­na-based biotech Suzhou Ri­bo Life Sci­ence and its Swe­den-based unit Ri­bo­cure Phar­ma­ceu­ti­cals to de­vel­op siR­NA ther­a­pies for meta­bol­ic dys­func­tion-as­so­ci­at­ed steato­hep­ati­tis

The en­zyme en­gi­neer­ing spe­cial­ists at Codex­is are giv­ing up on mak­ing their own ther­a­pies, in­stead fo­cus­ing on sell­ing its tech­nolo­gies and ser­vices to cus­tomers —